125 related articles for article (PubMed ID: 16004563)
1. Perlegen sciences, inc.
Peacock E; Whiteley P
Pharmacogenomics; 2005 Jun; 6(4):439-42. PubMed ID: 16004563
[TBL] [Abstract][Full Text] [Related]
2. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
Smart A; Martin P
Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. DxS Ltd.
Little S
Pharmacogenomics; 2003 Jan; 4(1):97-101. PubMed ID: 12517290
[TBL] [Abstract][Full Text] [Related]
5. How molecular medicine transforms policy (and everything else).
Kean MA; Batchelder KF
J Biolaw Bus; 2004; 7(3):16-9. PubMed ID: 15460603
[TBL] [Abstract][Full Text] [Related]
6. Personalized medicine: elusive dream or imminent reality?
Lesko LJ
Clin Pharmacol Ther; 2007 Jun; 81(6):807-16. PubMed ID: 17505496
[TBL] [Abstract][Full Text] [Related]
7. Novel technology and the development of pharmacogenetics within the pharmaceutical industry.
Gibson N; Jawaid A; March R
Pharmacogenomics; 2005 Jun; 6(4):339-56. PubMed ID: 16004553
[TBL] [Abstract][Full Text] [Related]
8. SNPs and haplotypes: genetic markers for disease and drug response (review).
Shastry BS
Int J Mol Med; 2003 Mar; 11(3):379-82. PubMed ID: 12579344
[TBL] [Abstract][Full Text] [Related]
9. The integration of molecular diagnostics with therapeutics. Implications for drug development and pathology practice.
Ross JS; Ginsburg GS
Am J Clin Pathol; 2003 Jan; 119(1):26-36. PubMed ID: 12520694
[TBL] [Abstract][Full Text] [Related]
10. Genomic sciences and the medicine of tomorrow.
Drews J
Nat Biotechnol; 1996 Nov; 14(11):1516-8. PubMed ID: 9634812
[No Abstract] [Full Text] [Related]
11. Is personalized medicine finally arriving?
Allison M
Nat Biotechnol; 2008 May; 26(5):509-17. PubMed ID: 18464779
[TBL] [Abstract][Full Text] [Related]
12. Helicos BioSciences.
Milos P
Pharmacogenomics; 2008 Apr; 9(4):477-80. PubMed ID: 18384261
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the value of genomic diagnostics: implications for clinical practice and public policy.
Issa AM
Adv Health Econ Health Serv Res; 2008; 19():191-206. PubMed ID: 19548519
[TBL] [Abstract][Full Text] [Related]
14. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
[TBL] [Abstract][Full Text] [Related]
15. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
16. Global gene mining and the pharmaceutical industry.
Knudsen LE
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):679-83. PubMed ID: 15979678
[TBL] [Abstract][Full Text] [Related]
17. Psychiatric Genomics, inc.
Palfreyman MG
Pharmacogenomics; 2002 May; 3(3):417-20. PubMed ID: 12052148
[TBL] [Abstract][Full Text] [Related]
18. Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality?
Vizirianakis IS
Pharmacogenomics; 2005 Oct; 6(7):701-11. PubMed ID: 16207147
[TBL] [Abstract][Full Text] [Related]
19. Rubicon Genomics, Inc.
Langmore JP
Pharmacogenomics; 2002 Jul; 3(4):557-60. PubMed ID: 12164778
[TBL] [Abstract][Full Text] [Related]
20. Use of whole-genome association scans in disease gene identification, drug discovery and development.
Roses AD; St Jean PL; Ehm MG
IDrugs; 2007 Nov; 10(11):797-804. PubMed ID: 17968762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
